CLOs on the Move


 
At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.com
  • 1 North Waukegan Road
    North Chicago, IL USA 60064
  • Phone: 847.932.7900

Executives

Name Title Contact Details
Allisyn Monteleone
Associate General Counsel Profile
Arya Sadeghi
Senior Counsel Profile
Laura Brake
Associate General Counsel Profile
Matt Bennett
Head of Sales, Teliso-V Profile
Paul Hammond
Associate General Counsel Profile

Similar Companies

Nektar

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar`s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

CuraScript

CuraScript is one of the nation's largest providers of specialty injectable and oral medications. CuraScript has been in the specialty pharmacy business since 1989. Between 1994 and August 1, 2000, the company operated as Coram Prescription Services

Human Care Systems, Inc.

HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence. Since 2008, HCS has worked with biopharma brand teams who want to deliver personalized, omni-channel programming with measured outcomes.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.